Protein arginine methyltransferases (PRMTs) regulate mRNA processing and maturation by modulating the activity of RNA-binding proteins through methylation. The cDNA for human PRMT1 (HRMT1L2) was recently identified. In this paper, we describe the complete genomic organization of the human PRMT1 gene (GenBank Accession No. AF222689), together with its precise chromosomal localization in relation to other neighboring genes. We have also examined its expression in a total RNA panel of 26 human tissues, the BT-474 breast carcinoma cell line, and 16 breast tumors. PRMT1, which spans 11.2 kb of genomic sequence on chromosome 19q13.3, is located in close proximity to the IRF3 and RRAS genes and is transcribed in the opposite direction. It is formed of 12 coding exons and 11 intervening introns, and shows structural similarity to other PRMT genes. Three PRMT1 isoforms exist as a result of alternative mRNA splicing. Amino acid sequence comparison of the splicing variants indicates that they are all enzymatically active methyl transferases, but with different N-terminal hydrophobic regions. PRMT1 expression was detected in a variety of tissues. We have shown that the relative prevalence of alternatively spliced forms of PRMT1 is different between normal and cancerous breast tissues. Although PRMT1 was not found to be hormonally regulated by steroid hormones in breast cancer cells, our results suggest that two variants of PRMT1 are down regulated in breast cancer.
The molecular mechanisms governing the transition from gene to protein have yet to be fully elucidated. Primary eukaryotic gene transcripts (pre-mRNAs) undergo a series of processing reactions to form functional, mature mRNA. RNA processing takes place in the nucleus through the action of a group of nuclear proteins, collectively referred to as the heterogeneous nuclear ribonucleoproteins (hnRNPs). hnRNPs play a regulatory role in mRNA maturation, stability, and export to the cytoplasm (1) . hnRNP activity, in turn, is governed by posttranslational modifications such as glycosylation (2) , phosphorylation (3) , and methylation (4) , which cooperatively regulate hnRNP binding and dissociation from RNA. Of particular interest is the protein arginine methylation event which produces N G ,N G -dimethylarginine, an amino acid present in the majority of hnRNPs. hnRNPs contain ϳ65% of the total cellular N G ,N G -dimethylarginine (5), indicating that this unusual modification plays an important role in regulating hnRNP activity.
The enzyme responsible for this methylation reaction is protein arginine methyltransferase (PRMT). PRMTs specifically methylate protein substrates that contain an RRG binding domain, a motif involved in RNA:RNA and RNA:protein interactions which consists of repeated glycine dipeptides interspersed with arginines and aromatic residues. PRMT1 methylates hnRNPs which contain an RRG box, such as hnRNP A1, in addition to other RNA-binding proteins with an RRG binding motif, such as nucleolin, fibrillarin, and ribosomal protein S2 (5, 6) . Arginine methylation is a cellular process which occurs over a wide range of eukaryotes, and PRMTs have been studied in several eukaryotic species. This enzyme was first isolated in 1988 from calf brain (7) . Two homologous proteins, PRMT1 and PRMT2 (also called HMT1 and RMT2) and the corresponding genes were later identified in yeast (8, 9) . Many recent studies have been performed on rodent and human PRMTs. Human PRMT1, also called HRMT1L2 or IR1B4, (10, 11) is 96% identical at the amino acid level to rat PRMT1 (6) . Human PRMT2, also called HRMT1L1, is 33% identical in amino acid sequence to human PRMT1 (10, 12) . Human PRMT3, was also recently cloned (13) .
In this study, we describe the complete genomic organization and chromosomal location of PRMT1. We have examined the differential expression of the three PRMT1 splicing variants in a large number of normal human tissues, the BT-474 breast carcinoma cell line, and breast tumors. Our preliminary data suggest that two variants of PRMT1 are down regulated in breast cancer.
MATERIALS AND METHODS
Chromosome 19 sequence analysis. Genomic sequences for chromosome 19 are available from the Lawrence Livermore National Laboratory database. We examined ϳ200 kb of nucleotide sequence (clone BC 42053), in the form of 90 separate contigs of variable lengths, spanning chromosome 19q13.3-q13.4. The chromosome 19 EcoRI restriction map (14) and long PCR strategies, were used to construct a contiguous area of the genomic area of interest. Bioinformatic approaches were used, as previously described (15) (16) (17) (18) (19) , to predict the presence of new genes and a putative arginine methyltransferase was identified. Blast search (20) and EcoRI restriction digestion analysis of the sequence of one adjacent BAC clone (R31181) allowed us to identify the relative position of this methyltransferase gene and other previously identified genes; RRAS and IRF3, along the same chromosomal region (19q13.3).
Protein structural analysis. The Baylor College of Medicine (BCM) search launcher was used to perform multiple alignment using Clustal X software (21) , and hydrophobicity studies. Phylogenetic trees were constructed using the Phylip software package (22) . Distance matrix analysis was performed using the "NeighborJoining/UPGMA" program, and parsimony analysis was done using the "Protpars" program (23) . Signal peptide was predicted using the SignalP (24) . Protein structure analysis was performed with the "SAPS" (structural analysis of protein sequence) program (25) .
Hormonal stimulation the BT-474 cell line. The breast cancer cell line BT-474 was purchased from the American Type Culture Collection (Rockville, MD). Cells were cultured in RPMI media (Gibco BRL, Gaithersburg, MD) supplemented with glutamine (200 mmol/L), bovine insulin (10 mg/L), fetal bovine serum (10%), antibiotics and antimycotics, in plastic flasks, to near confluency. The cells were then aliquoted into 24-well tissue culture plates and cultured to 50% confluency. The culture media were changed to phenol red-free media containing 10% charcoal-stripped fetal bovine serum 24 h prior to stimulation. Hormonal stimulation was performed by the addition of various steroid hormones, dissolved in 100% ethanol, to the culture media at a final concentration of 10 Ϫ8 M. Cells stimulated with 100% ethanol were included as negative controls. The cells were cultured for 24 h before mRNA extraction.
Human tissues. Total RNA isolated from 26 different human tissues was purchased from Clontech (Palo Alto, CA). Noncancerous breast tissues were obtained from women undergoing reduction mammoplasties. Breast tumor tissues were obtained from leftover frozen specimens submitted for steroid receptor analysis. Tissues were immediately frozen in liquid nitrogen after surgical resection.
RT-PCR analysis of PRMT1 expression. Total RNA was extracted from cells and tissues using Trizol reagent (Gibco BRL) according to the manufacturer's specifications. RNA concentration was determined spectrophotometrically. Two micrograms of total RNA was reverse transcribed into first strand cDNA using the Superscript preamplification system (Gibco BRL). After aligning all known PRMT1 homologous genes, two primers (PF and PR) ( Table 1 ; Fig. 1 ) were designed from areas with relatively low homology. The RT-PCR primers spanned at least 2 exons to avoid contamination by genomic DNA. Tissue cDNAs were amplified at various dilutions. PCR was performed in a 20 L reaction mixture containing 1 L of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 M dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ) on a Perkin-Elmer 9600 thermal cycler. An initial incubation at 94°C for 10 min was followed by 43 cycles consisting of a 94°C denaturing step (30 s) and a 67°C annealing/extension step (1 min). A final extension step at 67°C was included for 10 min. PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. Cloning and sequencing of PCR products. To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The inserts were sequenced from both directions, using vectorspecific primers, with an automated DNA sequencer.
RESULTS

Characterization of the PRMT1 Gene Sequence
Computer analysis of the contiguous genomic sequence of interest around chromosome 19q13.3-q13.4 predicted a gene comprised of 12 exons. To verify the existence and identity of this gene, the putative exons were subjected to sequence homology search against the human expressed sequence tag database (dbEST), and 10 EST clones with Ͼ98% homology were identified. A similar search of the GenBank sequence database identified the cDNA from the human PRMT1/ HRMT1L2 gene to be 100% homologous to the predicted exons. Thus, our genomic sequence was found to harbor the PRMT1 gene (please see also below).
Genomic Structure of the PRMT1 Gene
By comparing the genomic sequences of interest with the cDNA sequences of the known three PRMT1 gene isoforms (variants; v) as described by Scott et al. (10) , we were able to determine the genomic organization of the PRMT1 gene. Figure 1 demonstrates that the PRMT1 gene is made up of 12 (v3), 11 (v2) or 10 (v1) exons, separated by 11, 10, or 9 introns, respectively (all variants are included in our GenBank Submission No. AF222689). Interestingly, in variant 3, there is an in-frame stop codon in the middle of exon 3. A second downstream start codon resumes transcription. A schematic description of the variants is further shown in Fig. 2 .
The (27) . The stop codon is located at position 82-84 of exon 12, followed by a 3Ј untranslated region, and a typical polyadenylation signal (AATAAA) is located 12 bp upstream of the poly-A tail. More details of the sequence have been described in our GenBank submission, Accession No. AF222689.
Mapping and Chromosomal Localization of the PRMT1 Gene
The knowledge of extensive genomic sequence on chromosome 19q13.3 enabled us to precisely localize PRMT1 as well as two additional known genes, namely RRAS and IRF3, and to determine the direction of transcription, as shown in Fig. 3 . RRAS is the most telomeric, followed by IRF3 and PRMT1, respectively. PRMT1 is transcribed in the opposite direction of RRAS and IRF3. The distance between the RRAS and IRF3 genes was calculated to be 19.5 kb. PRMT1 is located 11.6 kb centromeric to IRF3.
Tissue Expression of PRMT1 Splice Variants
Screening of cDNA from a panel of 26 different tissues using gene-specific primers for exons 1 and 6 (PF/PR; Table 1 ) (exon numbers refers to our GenBank Submission No. AF222689) revealed that this gene is expressed in many tissues. Three bands were observed, representing PCR products of 502, 385, and 331 bp, in the tissues examined (Fig. 4) . The five tissues displaying the highest level of expression (cerebellum, mammary gland, prostate, brain, and thyroid) were cloned and sequenced. RT-PCR for actin and PSA (which exhibits tissue-restricted expression) were used as positive controls. The PSA gene was found to be highly expressed in the prostate, and to a lower extent in the mammary, thyroid, and salivary glands, as expected (28, 29) .
The tissue expression profile of the PRMT1 variants is summarized in Fig. 4 and Table 2 . Variant 1 is primarily expressed in the prostate, brain, heart, adrenal gland, mammary gland, colon, thyroid, and testicular tissues, and to a lower extent in many other tissues. The expression of the PRMT1-v2 is more predominant in heart, skeletal muscle, colon, and testicular tissues. PRMT-v3 is mainly expressed in the brain, cerebellum, thyroid, prostate, and mammary glands.
Differential Expression PRMT1 Splicing Variants in the BT-474 Breast Cancer Cell Lines
We used the steroid hormone receptor-positive breast carcinoma cell line BT-474 as a model system to evaluate whether PRMT1 expression is under steroid hormone regulation. This gene does not seem to be regulated significantly by estrogen, androgens, or progestins (Fig. 5) . However, only variant 3 was detected, in contrast to the data of Fig. 4 , which shows expression of all three variants in normal mammary tissue.
PRMT1 Expression in Breast Cancer
Expression of the PRMT1 gene was examined in 16 breast tumors and three noncancerous breast tissue The primers used were PF and PR, as described in Table 1 . For further discussion see text. specimens using RT-PCR. All three PRMT1 splicing variants were expressed in the noncancerous tissues. The gene is not expressed at all in two tumors (Fig. 6,  lanes 2 and 9) . Three of the tumors expressed all the PRMT1 variants (lanes 3, 6, and 16). Expression of PRMT1-v2 was not observed in 12 tumors while PRMT1-v3 was not expressed in 13 tumors. PRMT1-v1 was expressed at variable levels in the majority of the tumors (14/16) (Fig. 6 ). We thus conclude that, in comparison to normal tissues, tumors have the following expression patterns: (a) very frequent downregulation of variants 2 and 3 and (b) less frequent downregulation of variant 1.
Analysis of the PRMT1 Proteins
The predicted protein-coding regions of the PRMT1 gene are comprised of 1,032 bp (v1), 1,086 bp (v2), or 1,044 bp (v3), and encode 3 deduced polypeptides with a predicted molecular weight of 39.6, 41.5, and 39.9 kDa, excluding any posttranslational modifications, with theoretical isoelectric points of 5.4, 5.2, and 5.4, respectively. PRMT1 contains 343 (v1), 361 (v2) or 347 (v3) amino acids. In Fig. 7 , alignment of human PRMT proteins (for PRMT1 we used the longest variant, v2) and other non-human homologs is presented. Various areas of extensive protein sequence homology are evident, between the human PRMT members as well as the three rat orthologs and the yeast enzyme.
Furthermore, human PRMT1 protein has 96% amino acid sequence identity with the rat PRMT1, 45% identity with yeast PRMT1 and 34, 33, 29, and 28% identity with human PRMT3, rat PRMT3, human PRMT2, and rat PRMT2, respectively. To predict the phylogenetic relatedness of the human PRMT1 gene with other arginine methylotranferases, the amino acid sequences of these genes were aligned using the "Clustal X" multiple alignment program and a distance matrix tree was predicted using the Neighbor-joining/ UPGMA method (Fig. 8) . Phylogenetic analysis generated three clusters and grouped human PRMT1 with rat PRMT1, in accordance with previous studies (10, 13) and indicating that this group of genes probably arose from a common ancestral gene by duplication.
Examination of the hydrophobicity profile of the PRMT1 protein variants revealed three (v2 and v3) or two (v1) regions with long stretches of hydrophobic residues (Fig. 9) . The first of these occurs at the N-terminus, suggesting the presence of a putative signal peptide but software analysis (24) predicts these proteins as nonsecretory.
DISCUSSION
Protein arginine methyltransferases (PRMTs) play a role in the control of mRNA processing and maturation by modulating the activity of RNA-binding proteins. To date, three human PRMTs have been cloned. This study reports, for the first time, the structural characterization and genomic organization of the full-length human PRMT1 gene. Furthermore, the genomic region comprising the PRMT1, RRAS, and IRF3 genes was elucidated. Three PRMT1 splicing variants (v1, v2, v3) were identified, in agreement with previously reported data (10) . The PRMT1 gene is made up of 12 (v3), 11 (v2) or 10 (v1) exons, separated by 11, 10, or 9 introns, respectively. We examined the differential expression of the three PRMT1 isoforms in normal tissues, the BT-474 breast cancer cell line, and 16 breast tumors. PRMT1 was abundantly expressed in all samples, not surprisingly, given that methylation of RNA-binding proteins occurs in all cells. The relative predominance of the alternatively spliced forms of PRMT1, however, differed between tissues, as well as between normal breast tissue and breast cancers and BT-474 cells. PRMT1-v1 and PRMT1-v2 were significantly down regulated in most of the breast tumors. This gene is not regulated by estrogen, androgens, or progestins in BT-474 cells.
The biological function of PRMTs is to methylate RNA-binding proteins, particularly hnRNPs, which, in turn, mediate mRNA maturation, splicing, localization, and metabolism. The overall physiological role of PRMT1, however, is not clear. It has been reported that PRMT1 may be involved in certain signal transduction events. PRMT1 is able to interact with the intracytoplasmic domain of the Type 1 interferon (IFN) receptor, upregulating the antiproliferative effect of IFNs (10) . Another study reported that PRMT1 associates with the product of the immediate-early response gene TIS21, which acts as a negative regulator of cell proliferation in response to external signals. TIS21 modulates PRMT1 enzymatic activity in terms of substrate specificity, and upregulates PRMT1 catalytic efficiency. The implication of PRMT1 as an external signal modulator is logical, as gene expression in response to external signals may be under transcriptional or posttranscriptional control. The latter may involve mRNA splicing, localization, or stability, all controlled by PRMT1. PRMT1 may also be of importance prior to mRNA processing. The recently identified coactivator-associated arginine methyltransferase 1 (CARM1), which is homologous to protein arginine methyltransferases, is incorporated into transcription initiation complexes, and methylates proteins in this complex in order to activate transcription (30) . The above studies collectively suggest a role for PRMTs at the transcription and/or translation level during the cellular response to external signals.
No previous studies regarding PRMT1 expression and cancer have been reported. However, PRMT substrates, including hnRNPs (31), fibrillarin (32) , and ribosomal protein S2 (33) are overexpressed in some tumors. Furthermore, a dramatic increase in cellular arginine methylation has been reported in certain types of cancer (34 -36) . Additionally, the N-terminal region of the rat PRMT1 and PRMT2 proteins contains a Src homology 3 (SH3) domain (10, 37) .
The development and progression of cancer may alter the expression of certain genes. Tumor-specific modulation of gene expression may occur at the posttranscriptional level, and include such processes as alternative splicing, yet the functional significance of PRMT1 splicing in breast cancer is unclear. Amino acid sequence comparison of the splicing variants indicates that they are all enzymatically active methyltransferases. The isoforms may, however, interact differently with members of signal transduction pathways or components of the transcriptional activation machinery. Here, we report the absence of PRMT1-v1 and 2 in the breast cancer cell line BT-474, and downregulation of variants 2 and 3 in breast tumors. It will be interesting to determine if the alterations are valuable for breast cancer prognosis or prediction of therapeutic response.
